Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 196

1.

Pulmonary exacerbations in cystic fibrosis with negative bacterial cultures.

Zemanick ET, Wagner BD, Harris JK, Wagener JS, Accurso FJ, Sagel SD.

Pediatr Pulmonol. 2010 Jun;45(6):569-77. doi: 10.1002/ppul.21221.

2.

Bronchoscopy-guided antimicrobial therapy for cystic fibrosis.

Jain K, Wainwright C, Smyth AR.

Cochrane Database Syst Rev. 2013 Dec 23;(12):CD009530. doi: 10.1002/14651858.CD009530.pub2. Review. Update in: Cochrane Database Syst Rev. 2016;(1):CD009530.

PMID:
24363033
3.

Bronchoscopy-guided antimicrobial therapy for cystic fibrosis.

Jain K, Wainwright C, Smyth AR.

Cochrane Database Syst Rev. 2016 Jan 21;(1):CD009530. doi: 10.1002/14651858.CD009530.pub3. Review.

PMID:
26797965
4.

Nebulized tobramycin in the treatment of adult CF pulmonary exacerbations.

Al-Aloul M, Nazareth D, Walshaw M.

J Aerosol Med Pulm Drug Deliv. 2014 Aug;27(4):299-305. doi: 10.1089/jamp.2013.1055.

PMID:
24219814
6.

Reduction in Pseudomonas aeruginosa sputum density during a cystic fibrosis pulmonary exacerbation does not predict clinical response.

Lam JC, Somayaji R, Surette MG, Rabin HR, Parkins MD.

BMC Infect Dis. 2015 Mar 22;15:145. doi: 10.1186/s12879-015-0856-5.

7.

Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial.

Saiman L, Anstead M, Mayer-Hamblett N, Lands LC, Kloster M, Hocevar-Trnka J, Goss CH, Rose LM, Burns JL, Marshall BC, Ratjen F; AZ0004 Azithromycin Study Group..

JAMA. 2010 May 5;303(17):1707-15. doi: 10.1001/jama.2010.563.

PMID:
20442386
8.

Inflammation and airway microbiota during cystic fibrosis pulmonary exacerbations.

Zemanick ET, Harris JK, Wagner BD, Robertson CE, Sagel SD, Stevens MJ, Accurso FJ, Laguna TA.

PLoS One. 2013 Apr 30;8(4):e62917. doi: 10.1371/journal.pone.0062917.

9.

Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosis.

Waters V, Ratjen F.

Cochrane Database Syst Rev. 2015 Nov 2;(11):CD006961. doi: 10.1002/14651858.CD006961.pub3. Review.

PMID:
26522473
10.

Molecular analysis of changes in Pseudomonas aeruginosa load during treatment of a pulmonary exacerbation in cystic fibrosis.

Reid DW, Latham R, Lamont IL, Camara M, Roddam LF.

J Cyst Fibros. 2013 Dec;12(6):688-99. doi: 10.1016/j.jcf.2013.03.008.

11.

Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis.

Mayer-Hamblett N, Kronmal RA, Gibson RL, Rosenfeld M, Retsch-Bogart G, Treggiari MM, Burns JL, Khan U, Ramsey BW; EPIC Investigators..

Pediatr Pulmonol. 2012 Feb;47(2):125-34. doi: 10.1002/ppul.21525.

12.
13.
14.

Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis.

Langton Hewer SC, Smyth AR.

Cochrane Database Syst Rev. 2014 Nov 10;(11):CD004197. doi: 10.1002/14651858.CD004197.pub4. Review.

PMID:
25383937
15.

Acute effects of viral respiratory tract infections on sputum bacterial density during CF pulmonary exacerbations.

Chin M, De Zoysa M, Slinger R, Gaudet E, Vandemheen KL, Chan F, Hyde L, Mah TF, Ferris W, Mallick R, Aaron SD.

J Cyst Fibros. 2015 Jul;14(4):482-9. doi: 10.1016/j.jcf.2014.11.009.

PMID:
25544473
16.

Induced sputum compared to bronchoalveolar lavage in young, non-expectorating cystic fibrosis children.

Blau H, Linnane B, Carzino R, Tannenbaum EL, Skoric B, Robinson PJ, Robertson C, Ranganathan SC.

J Cyst Fibros. 2014 Jan;13(1):106-10. doi: 10.1016/j.jcf.2013.05.013.

17.
18.

Early anti-pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'.

Treggiari MM, Rosenfeld M, Mayer-Hamblett N, Retsch-Bogart G, Gibson RL, Williams J, Emerson J, Kronmal RA, Ramsey BW; EPIC Study Group..

Contemp Clin Trials. 2009 May;30(3):256-68. doi: 10.1016/j.cct.2009.01.003.

19.

The adult cystic fibrosis airway microbiota is stable over time and infection type, and highly resilient to antibiotic treatment of exacerbations.

Fodor AA, Klem ER, Gilpin DF, Elborn JS, Boucher RC, Tunney MM, Wolfgang MC.

PLoS One. 2012;7(9):e45001. doi: 10.1371/journal.pone.0045001.

20.

Effect of bronchoalveolar lavage-directed therapy on Pseudomonas aeruginosa infection and structural lung injury in children with cystic fibrosis: a randomized trial.

Wainwright CE, Vidmar S, Armstrong DS, Byrnes CA, Carlin JB, Cheney J, Cooper PJ, Grimwood K, Moodie M, Robertson CF, Tiddens HA; ACFBAL Study Investigators..

JAMA. 2011 Jul 13;306(2):163-71. doi: 10.1001/jama.2011.954.

PMID:
21750293

Supplemental Content

Support Center